In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Decision on EU marketing authorisation for this population expected by September 2024
GSK and Flagship to jointly fund up to $150 million upfront
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Subscribe To Our Newsletter & Stay Updated
